Corient Capital Partners, LLC Sorrento Therapeutics, Inc. Transaction History
Corient Capital Partners, LLC
- $1.34 Billion
- Q3 2022
A detailed history of Corient Capital Partners, LLC transactions in Sorrento Therapeutics, Inc. stock. As of the latest transaction made, Corient Capital Partners, LLC holds 14,913 shares of SRNE stock, worth $4,921. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,913
Previous 14,913
-0.0%
Holding current value
$4,921
Previous $30,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SRNE
# of Institutions
13Shares Held
5.48MCall Options Held
0Put Options Held
0-
B. Riley Securities, Inc. Los Angeles, CA5.22MShares$1.72 Million1.01% of portfolio
-
Swisspartners Ltd. Vaduz, N2110KShares$36,3000.12% of portfolio
-
Lattice Capital Management, LLC51.8KShares$17,0940.01% of portfolio
-
Klcm Advisors, Inc.30KShares$9,9000.0% of portfolio
-
Slate Stone Wealth, LLC21.4KShares$7,0720.0% of portfolio
About Sorrento Therapeutics, Inc.
- Ticker SRNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 449,952,000
- Market Cap $148M
- Description
- Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...